Tamsulosin for Early Catheter Removal After Rectal Cancer Surgery
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study aims to systematically evaluate the safety and efficacy of different early urinary catheter removal strategies following radical resection of mid-low rectal cancer. Current clinical practice faces controversy regarding the optimal timing of catheter removal (24 hours vs. 48 hours) and lacks precise preventive measures for patients at high risk of postoperative acute urinary retention (AUR). To address these issues, this study is designed as a three-arm randomized controlled trial, directly comparing three management protocols: catheter removal at 24 hours postoperatively, catheter removal at 48 hours postoperatively, and urinary catheter removal within 24 hours combined with prophylactic tamsulosin. The primary endpoint is the rate of recatheterization within 7 days after the initial removal, with secondary endpoints comprehensively assessing urinary tract infections, voiding function, and postoperative complications. The ultimate goal is to provide high-quality evidence-based medical evidence to establish a precise and standardized clinical pathway for postoperative catheter management.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rak odbytnicy przed operacją.
- •Guz znajduje się w odbytnicy, w odległości do 10 cm od odbytu.
- •Pacjenci kierowani na operację odbytnicy metodą laparoskopową lub robotyczną.
- •Wcześniejsze stadium raka ustalone przed operacją lub po leczeniu.
✗ Disqualifies
- •Wcześniejsze operacje w obrębie jamy brzusznej, miednicy lub operacje dotyczące prostaty/macicy.
- •Problemy z oddawaniem moczu przed operacją lub choroby takie jak choroba Parkinsona.
- •Problemy z pęcherzem, takie jak nadreaktywność lub wcześniejsze trudności z oddawaniem moczu.
- •Potrzeba usunięcia innych narządów miednicy podczas operacji (np. pęcherza, macicy).
Simplified criteria — AI translation
Trial details
- Last updated (source)
- September 29, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Harbin Medical University Cancer Hospital
Harbin, China
The First Hospital of Jilin University
Changchun, China
Trial contact
Yuchen Guo Yuchen Guo
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/30/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.